Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required)
Notice Number:
NOT-CA-24-085

Key Dates

Release Date:
July 22, 2024
Estimated Publication Date of Notice of Funding Opportunity :
September 25, 2024
First Estimated Application Due Date:
February 24, 2025
Earliest Estimated Award Date:
March 01, 2026
Earliest Estimated Start Date:
March 01, 2026
Related Announcements

None

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) intends to issue a U10 NCI National Clinical Trials Network (NCTN) – Canadian Collaborating Clinical Trials Network notice of funding opportunity (NOFO). The NCTN Canadian Collaborating Clinical Trials Network will be a full partner with the U.S. Network in the conduct of large-scale, multi-site clinical trials and help provide regulatory expertise/oversight for the conduct of NCTN trials in Canada. This. The primary goal of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and advanced imaging trials across a broad range of cancers, modalities, and diverse patient populations with relevance to the U.S. patient population as part of the NCI's overall clinical research program for adults, adolescents and young adults, and children with cancer. The NCTN also conducts umbrella/basket trials and rare tumor trials, when an extensive, national patient catchment area is required.

This Notice of Intent to Publish is being provided to allow sufficient time for the applicant to develop a strong application.
The NOFO is expected to be published in Fall 2024 with only one expected application due date in late February 2025.
 

Research Initiative Details

This Notice encourages Canadian investigators with clinical cancer treatment trial expertise in adult oncology to begin to consider applying for this NOFO. The funding provides support for the organizational, administrative, and scientific management of the Canadian Collaborating Clinical Trials Network (CCCTN) with respect to the oversight of conduct of NCTN trials in Canadan and to the collective management of the overall NCTN Program. This funding support also extends to the Canadian Collaborating Clinical Trials Network, on occasion, leading large, multi-site NCTN cancer treatment trials that are also relevant to the U.S. patient population. The funding provides support for robust clinical trial statistical analysis plans as well as appropriate data management, serious adverse event reporting, and monitoring of all aspects of clinical trial conduct for the NCTN trials that the CCCTN participates in and/or leads, including support for Canadian site accrual and ensuring timely trial completion and data validity.

Funding Information

Estimated Total Funding

NCI intends to commit $3.8 million in FY 2026

Expected Number of Awards

One

Estimated Award Ceiling

The application budget is not limited but need to reflect the actual needs of the proposed project. The total project period requested may not exceed 6 years.
 

Primary Assistance Listing Number(s)

93.394, 93.395

Anticipated Eligible Organizations

Only the current Canadian Collaborating Clinical Trials Network awardee, supported under RFA-CA-17-058 is eligible to apply.

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Margaret Mooney, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6006
Email: NCINCTNRFA@mail.nih.gov